Pulmatrix Net Cash Flow 2014-2025 | PULM

Pulmatrix net cash flow from 2014 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Pulmatrix Net Cash Flow 2014-2025 | PULM

Pulmatrix net cash flow from 2014 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$214.8B
Amgen (AMGN)$160.4B
Gilead Sciences (GILD)$135.3B
Vertex Pharmaceuticals (VRTX)$119B
Bristol Myers Squibb (BMY)$97.8B
CSL (CSLLY)$78.3B
GSK (GSK)$74.7B
Regeneron Pharmaceuticals (REGN)$59.4B
Alnylam Pharmaceuticals (ALNY)$42.3B
Argenex SE (ARGX)$35B
BioNTech SE (BNTX)$26.7B
Royalty Pharma (RPRX)$19.9B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.9B
Illumina (ILMN)$15.5B
Genmab (GNMSF)$14.5B
Genmab (GMAB)$14.1B
Incyte (INCY)$13.3B
Moderna (MRNA)$12.5B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
Ascendis Pharma (ASND)$10.8B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exact Sciences (EXAS)$9.8B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Legend Biotech (LEGN)$7.7B